Most Recent Articles about JNJ
The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix http://www.zacks.com/stock/news/417279/the-zacks-analyst-blog-highlights-johnson-johnson-apple-goldman-sachs-ibm-and-netflix?cid=CS-ZC-FT-417279 May 21, 2019 - The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs http://www.zacks.com/research-daily/416895/top-analyst-reports-for-johnson-johnson-apple-goldman-sachs?cid=CS-ZC-FT-416895 May 20, 2019 - Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
AbbVie's Brain Cancer Candidate Fails in Phase III Study http://www.zacks.com/stock/news/416716/abbvies-brain-cancer-candidate-fails-in-phase-iii-study?cid=CS-ZC-FT-416716 May 20, 2019 - AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

Related Companies

Name Exchange Price Mkt Cap
PFE Pfizer, Inc. NYSE $43.01 $252.13B
NVS Novartis AG NYSE $85.13 $197.65B
MRK Merck & Company, Inc. NYSE $70.42 $187.28B
ABBV AbbVie Inc. NYSE $95.37 $144.42B
ABT Abbott Laboratories NYSE $67.67 $118.71B
Sector: Health Care > Industry: Major Pharmaceuticals